Different progression of tumor xenografts between mucin-producing and mucin-non-producing mammary adenocarcinoma-bearing mice

Cancer Research

Volumn 66, Issue 12, 2006, Pages 6175-6182

  Sugihara, Ippei ^a   Yoshida, Masanobu ^a   Shigenobu, Tatsuro ^a   Takagi, Hiroaki ^a   Maruyama, Koji ^a   Takeuchi, Noriko ^a,b   Toda, Munetoyo ^a,b   Inoue, Mizue ^a,b   Nakada, Hiroshi ^a,b  

^a KYOTO SANGYO UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; EPIGLYCANIN; GAMMA INTERFERON; GLYCOPROTEIN; INTERLEUKIN 12; MESSENGER RNA; MUCIN; MUCIN 2; PROSTAGLANDIN E2; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST ADENOCARCINOMA; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME INDUCTION; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SPLEEN; TUMOR GROWTH; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYTOKINES; DINOPROSTONE; DISEASE PROGRESSION; ENZYME INDUCTION; ETODOLAC; MACROPHAGES, PERITONEAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED A; MUCINS; NEOVASCULARIZATION, PATHOLOGIC; TH1 CELLS;

EID: 33745728158     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3663     Document Type: Article

References (49)

1. Marnett LJ. Aspirin and the potential role of prostaglaiidins in colon cancer. Cancer Res 1992;52:5575-89.
2. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996;271:33157-60.
3. Eberhart CE, DuBois RN. Eicosanoids and the gastrointestinal tract Gastroenterology 1995;109:285-301.
4. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997;57:1276-80.
5. Tucker ON, Dannenberg AJ, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999;59:987-90.
6. Klimp AH, Hollema H, Kempinga C, van der Zee AG, Vries EG, Daemen T. Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. Cancer Res 2001;61:7305-9.
7. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000;105:1589-94.
8. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in ApcΔ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-9.
9. Inaba T, Sano H, Kawahito Y, et al. Induction of cyclooxygenase-2 in monocyte/macrophage by mucins secreted from colon cancer cells. Proc Natl Acad Sci U S A 2003;100:2736-41.
10. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
11. 2 in human colon cancer cells. Cancer Res 1998;58:362-6.
12. Stolina M, Sharma S, Lin Y, et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 2000;164:361-70.
13. Gasparini G, Longo R, Sarmiento R, Morabito A. Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol 2003;4:605-15.
14. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogencsis induced by colon cancer cells. Cell 1998;93:705-16.
15. 2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci U S A 2004;101:591-6.
16. Wang D, DuBois RN. Cyclooxygenase 2-derived prostaglandin E2 regulates the angiogenic switch. Proc Natl Acad Sci U S A 2004;101:415-6.
17. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-11.
18. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 1997;94:3336-40.
19. 2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem 2002;277:50828-33.
20. Kakiuchi Y, Tsuji S, Tsujii M, et al. Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis. Cancer Res 2002;62:1567-72.
21. Kim YS, Gum J, Jr., Brockhausen I. Mucin glycoproteins in neoplasia. Glycoconj J 1996;13:693-707.
22. Miyake M, Taki T, Hitomi S, Hakomori S. Correlation of expression of H/Le(y)/Le(b) antigens with survival in patients with carcinoma of the lung. N Engl J Med 1992;327:14-8.
23. Codington JF, Sanford BH. Jeanloz RW. Cell-surface glycoproteins of two sublines of the TA3 tumor. J Natl Cancer Inst 1973;51:585-91.
24. Codington JF, Haavik S. Epiglycanin-a carcinoma-specific mucin-type glycoprotein of the mouse TA3 tumor. Glycobiology 1992;2:173-80.
25. Codington JF, Klein G, Cooper AG, Lee N, Brown MC, Jeanloz RW. Further studies on the relationship between large glycoprotein molecules and allotransplantability in the TA3 tumor of the mouse: studies on segregating TA3-HA hybrids. J Natl Cancer Inst 1978;60:811-8.
26. Miller SC, Codington JF, Klein G. Further studies on the relationship between allotransplantability and the presence of the cell surface glycoprotein epiglycanin in the TA3-MM mouse mammary carcinoma ascites cell. J Natl Cancer Inst 1982;68:981-8.
27. Fung, PY, Longenecker BM. Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a mutine mammary adenocarcinoma (TA3-HA). Cancer Res 1991;51:1170-6.
28. Numata Y, Nakada H, Fukui S, et al. A monoclonal antibody directed to Tn antigen. Biochem Biophys Res Commun 1990;170:981-5.
29. Baeckstrom D, Hansson GC, Nilsson O, Johansson C, Gendler SJ, Lindholm L. Purification and characterization of a membrane-bound and a secreted mucintype glycoprotein carrying the carcinoma-associated sialyl-Le(a) epitope on distinct core proteins. J Biol Chem 1991;266:21537-47.
30. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
31. Kalinski P, Smits HH, Schuitemaker JH, et al. IL-4 is a mediator of IL-12p70 induction by human Th2 cells: reversal of polarized Th2 phenotype by dendritic cells. J Immunol 2000;165:1877-81.
32. Fukumura D, Xavier R, Sugiura T, et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998;94:715-25.
33. Tsunawaki S, Sporn M, Ding A, Nathan C. Deactivation of macrophages by transforming growth factor-β. Nature 1988;334:260-2.
34. Ghosh P, Komschlies KL, Cippitelli M, et al. Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth, J Natl Cancer Inst 1995;87:1478-83.
35. 2 is a potent inhibitor of human interleukin 12 production. J Exp Med 1995;181:775-9.
36. 2 production and its suppressive role in Th1 activation in Th2-dominant BALB/c mice. J Immunol 2003;170:757-64.
37. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995;13:251-76.
38. + cells. J Immunol 1996;156:1722-7.
39. Yokoigawa N, Takeuchi N, Toda M, et al. Over-production of PGE2 in peripheral blood monocytes of gastrointestinal cancer patients with mucins in their bloodstream. Cancer Lett In press 2006.
40. Thingstad T, Vos HL, Hilkens J. Biosynthesis and shedding of epiglycanin: a mucin-type glycoprotein of the mouse TA3Ha mammary carcinoma cell. Biochem J 2001;353:33-40.
41. Sonoshita M, Takaku K, Sasaki N, et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(A716) knockout mice. Nat Med 2001;7:1048-51.
42. Pelus LM, Bookman RS. Increased prostaglandin synthesis by macrophages from tumor-bearing mice. J Immunol 1979;123:2118-25.
43. Handel-Fernandez ME, Cheng X Herbert LM, Lopez DM. Down-regulation of IL-12, not a shift from a T helper-1 to a T helper-2 phenotype, is responsible for impaired IFN-γ production in mammary tumor-bearing mice. J Immunol 1997;158:280-6.
44. Manetti R, Gerosa F, Giudizi MG, et al. Interleukin 12 induces stable priming for interferon γ (IFN-γ) production during differentiation of human T helper (Th) cells and transient IFN-γ production in established Th2 cell clone. J Exp Med 1994;179:1273-83.
45. Heizel FP, Schoenhaut DS, Rerko RM, Rosser LE, Gately MK. Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med 1993;177:1505-9.
46. Novak TJ, Rothenberg EV. cAMP inhibits induction of interleukin 2 but not of interleukin 4 in T cells. Proc Natl Acad Sci U S A 1990;87:9353-7.
47. Demeure CE, Wu CY, Shu U et al. In vitro maturation of human neonatal CD4 T lymphocytes. II. Cytokines present at priming modulate the development of lymphokine production. J Immunol 1994;152:4775-82.
48. Kodama T, Freeman M, Rohrer L, Zabrecky J, Matsudaira P, Krieger M. Type 1 macrophage scavenger receptor contains á-helical and collagen-like coiled coils. Nature 1990;343:531-5.
49. Hampton RY, Golenbock DT, Penman M, Krieger M, Raetz CR. Recognition and plasma clearance of endotoxin by scavenger receptors. Nature 1991;352:342-4.